Laurus Labs Limited has completed the US Food and Drug Administration (USFDA) inspection of its API facilities in Units 1 & 3 at Parawada, Visakhapatnam, Andhra Pradesh, with two observations.
In a press release issued here, the company said the observations ``are only procedural in nature.''
``This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection,'' it added.
Laurus Labs' scrip lost 1.87 per cent on the Bombay Stock Exchange on Monday to end at Rs 526.35.